Adherence to Long-Term Therapies - Evidence for Action
(2003; 211 pages) Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentAcknowledgements
Afficher le documentScientific writers
Afficher le documentIntroduction
Afficher le documentTake-home messages
Ouvrir ce répertoire et afficher son contenuSection I - Setting the scene
Ouvrir ce répertoire et afficher son contenuSection II - Improving adherence rates: guidance for countries
Fermer ce répertoireSection III - Disease-Specific Reviews
Ouvrir ce répertoire et afficher son contenuChapter VII - Asthma
Ouvrir ce répertoire et afficher son contenuChapter VIII - Cancer (Palliative care)
Ouvrir ce répertoire et afficher son contenuChapter IX - Depression
Ouvrir ce répertoire et afficher son contenuChapter X - Diabetes
Ouvrir ce répertoire et afficher son contenuChapter XI - Epilepsy
Ouvrir ce répertoire et afficher son contenuChapter XII - Human immunodeficiency virus and acquired immunodeficiency syndrome
Fermer ce répertoireChapter XIII - Hypertension
Afficher le document1. Prevalence of adherence to pharmacotherapy in patients with hypertension
Afficher le document2. Impact of adherence on blood pressure control and cardiovascular outcome
Afficher le document3. Adherence to non-pharmacological treatment
Afficher le document4. Factors contributing to adherence
Afficher le document5. Interventions for improving adherence
Afficher le document6. Conclusions
Afficher le document7. References
Ouvrir ce répertoire et afficher son contenuChapter XIV - Tobacco smoking cessation
Ouvrir ce répertoire et afficher son contenuChapter XV - Tuberculosis
Ouvrir ce répertoire et afficher son contenuAnnexes
Ouvrir ce répertoire et afficher son contenuWhere to find a copy of this book
 

Chapter XIII - Hypertension

Clinical trials have demonstrated that the treatment of mild-to-moderate hypertension can reduce the risk of stroke by 30 to 43% (1 - 4) and of myocardial infarction by 15% (5). Other costly consequences of untreated hypertension can also be prevented or minimized by effective treatment. Examples of the benefits of treatment include reduction in risk of cardiac failure, reduction in incidence of dementia (6), preservation of renal function and prevention of blindness in diabetic patients with hypertension (7 - 9).

Traditionally, the term compliance has been employed to mean the extent to which the patient, when taking a drug, complies with the clinician's advice and follows the regimen (10). However, the new era of patient-oriented care has led to the use of this term being questioned, and alternative terms such as adherence, persistence and concordance have been suggested (11 - 14).

In addition to the confusing terminology in the area of adherence, there has been controversy over the use of 80% as a cut-off point to distinguish adherence from nonadherence. In most studies, nonadherence has been considered to occur when patients do not take ≥ 80% of their prescribed antihypertensive drugs (15,16).

Whatever the definition, poor adherence to treatment is the most important cause of uncontrolled blood pressure (13,14,17) and only 20 to 80% of patients receiving treatment for hypertension in real-life situations are considered to be "good compliers" (18).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013